Clinical impact of selective and nonselective beta‐blockers on survival in patients with ovarian cancer
Abstract
Preclinical evidence has suggested that sustained adrenergic activation can promote ovarian cancer growth and metastasis. The authors examined the impact of beta‐adrenergic blockade on the clinical outcome of women with epithelial ovarian, primary peritoneal, or fallopian tube cancers (collectively, epithelial ovarian cancer [EOC]).
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Aug 24, 2015
- Source ID
- 10.1002/cncr.29392
Entities
People
- Alpa M. Nick
- Anil K. Sood
- Diana L. Urbauer
- Jack L. Watkins
- Kathryn C. Squires
- Koji Matsuo
- Lois M. Ramondetta
- Pedro T. Ramirez
- Premal H. Thaker
- Robert L Coleman
- S. Kumar
- Susan K. Lutgendorf
Organizations
- Mayo Clinic
- National Institutes of Health
- RGK Foundation
- United States Department of Defense
- University of Iowa
- University of Texas at Austin
- Washington University in St. Louis